Source:http://linkedlifedata.com/resource/pubmed/id/14520092
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
10
|
pubmed:dateCreated |
2003-10-1
|
pubmed:abstractText |
Cancer chemoprevention is a rapidly evolving approach to reverse or inhibit carcinogenesis, and there is active interest in development of effective chemopreventive agents against head and neck cancers. The retinoids are archetypal chemopreventive agents for oral premalignant lesions. They have significant clinical effect, but widespread use is limited by significant clinical toxicity. The Bowman-Birk Inhibitor is one of several nontoxic compounds exhibiting both potent anticarcinogenic activity and minimal toxicity. The purposes of the study were to summarize the preclinical and clinical development of Bowman-Birk Inhibitor and a Bowman-Birk Inhibitor concentrate against oral premalignant lesions and to evaluate Neu immunohistochemical staining intensity for lesions and simultaneously obtained biopsy specimens of normal-appearing mucosa from the Phase IIa Bowman-Birk Inhibitor concentrate oral leukoplakia chemoprevention trial.
|
pubmed:grant | |
pubmed:keyword | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anticarcinogenic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Plant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/Trypsin Inhibitor, Bowman-Birk...,
http://linkedlifedata.com/resource/pubmed/chemical/Trypsin Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/alpha-Amylases
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0023-852X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
113
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1687-702
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:14520092-Animals,
pubmed-meshheading:14520092-Anticarcinogenic Agents,
pubmed-meshheading:14520092-Chemoprevention,
pubmed-meshheading:14520092-Head and Neck Neoplasms,
pubmed-meshheading:14520092-Humans,
pubmed-meshheading:14520092-Immunohistochemistry,
pubmed-meshheading:14520092-Leukoplakia, Oral,
pubmed-meshheading:14520092-Plant Proteins,
pubmed-meshheading:14520092-Receptor, erbB-2,
pubmed-meshheading:14520092-Trypsin Inhibitor, Bowman-Birk Soybean,
pubmed-meshheading:14520092-Trypsin Inhibitors,
pubmed-meshheading:14520092-alpha-Amylases
|
pubmed:year |
2003
|
pubmed:articleTitle |
Development of the Bowman-Birk inhibitor for oral cancer chemoprevention and analysis of Neu immunohistochemical staining intensity with Bowman-Birk inhibitor concentrate treatment.
|
pubmed:affiliation |
Department of Otolaryngology-Head and Neck Surgery, Chao Family Comprehensive Cancer Center, University of California-Irvine, 101 The City DriveSouth, Bldg. 25, Suite 191, Orange, CA 92868, USA. wbarmstr@uci.edu
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Review
|